Viral Vector and Plasmid DNA Manufacturing Market 2026: Growth Analysis by Manufacturers, Regions, Types and Applications

March 08 16:18 2019

Viral Vector and Plasmid DNA Manufacturing Market
Viral Vector and Plasmid DNA Manufacturing Market to Surpass US$ 1.7 Billion by 2026, Owing to Increasing Research and Development Activities of Viral Vector and Plasmid DNA

Viral Vector and Plasmid DNA Manufacturing Marketby Product Type (Viral Vector, Plasmid DNA, and Nonviral Vector), by Application (Cancer, Inherited disease, Viral Infection, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 290.0 million in 2017, and is projected to exhibit a CAGR of 22.5% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the global viral vector and plasmid DNA manufacturing market include, Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, Transgene SA, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, uniQure, MassBiologics, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.

Get a PDF Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/962

Research and development of novel viral vector and plasmid DNA by market players is expected to augment the market growth

Key players in the market are focused on research and development of novel viral vector and plasmid DNA, in order to treat complex cases and address critical unmet needs of patients. For instance, in June 2016, Penn Medicine launched a new program 3.0 Adeno Associated Vector (AAV) to develop new generation viral vector for better treatment of inherited and other diseases.

Similarly, Medigen’s innovative JEV live-attenuated vaccine, uses iDNA technology for preparation of safer vaccines against Japanese Encephalitis Virus (JEV) infections. The study results were positive and there is possibility of using this vaccine in Japanese Encephalitis Virus. iDNA vaccine includes genetic and physical stability, ease of production, and high purity of DNA vaccines, as well as high efficacy of live-attenuated vaccines.

Moreover, launch of new viral vector and plasmid DNA products, is expected to boost the market growth during the forecast period. For instance, in October 2018, Valneva Austria GmbH received approval from the U.S. Food and Drug Administration (FDA) for IXIARO vaccine to use in prevention of disease caused by JEV in persons 2 months of age and older.

Browse 25 Market Data Tables and 27 Figures spread through 169 Pages and in-depth TOC on ‘Human Viral Vector and Plasmid DNA Manufacturing Market’- Global Forecast to 2026, by Product Type (Viral Vector, Plasmid DNA, and Nonviral Vector), by Application (Cancer, Inherited disease, Viral Infection, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the viral vector and plasmid DNA manufacturing market, click the link below:

https://www.coherentmarketinsights.com/market-insight/viral-vectors-and-plasmid-dna-manufacturing-market-962

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance its r product portfolio. For instance, in March 2016, Spark Therapeutics acquired Genable Technologies, a company involved in developing new gene medicines to treat inherited retinal disease (IRD).

Key Takeaways of the Viral Vector and Plasmid DNA Manufacturing Market:

The viral vector and plasmid DNA manufacturing market is expected to exhibit a CAGR of 22.5 % over the forecast period, owing to increasing prevalence of cancer, inherited diseases, and viral infection

Among product type, the viral vector segment held dominant position in the viral vector and plasmid DNA manufacturing market in 2018, as majority of research and development activities are done for viral vector, owing to increasing demand for gene therapy for a variety of treatment options such as cancer.

Among application, cancer segment held dominant position in the viral vector and plasmid DNA manufacturing market in 2018. For instance, in September 2018, World Health Organization (WHO) stated that cancer is the second largest cause of deaths, globally.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Phone: +1-206-701-6702
Address:1001 4th Ave, #3200
City: Seattle
State: Washington
Country: United States
Website: https://www.coherentmarketinsights.com/insight/request-customization/962

  Categories: